Literature DB >> 20668898

Neuropsychological measures in clinical practice.

M Francesca Possa1.   

Abstract

Cognitive decline in multiple sclerosis can appear early in the course of the disease and may not be evident to the clinician if not investigated formally. Clinical neuropsychological evaluation with these patients has main peculiarities: disabilities, fatigue, relapses, medical treatment, psychological problems, that have to be seriously taken into consideration in choosing the tests and interpreting the profile. The peculiarity of cognitive decline in MS suggests an examination primarily of attentive-executive and memory domains, with Pasat and Symbol Digit Modalities Test, strongly recommended, together with memory test. The utilization of extensive or brief cognitive batteries depends on the different goals of the neuropsychological evaluation. It is important to find a screening procedure to be used by neurologists to identify the patients to be sent to an early formal evaluation, in consideration of the interference of cognitive profile with fundamental aspects of individual functioning, included adherence to rehabilitation and pharmacological treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20668898     DOI: 10.1007/s10072-010-0374-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  2 in total

1.  Motor fatigue is associated with asymmetric connectivity properties of the corticospinal tract in multiple sclerosis.

Authors:  Christian Bauer; Tim B Dyrby; Finn Sellebjerg; Kathrine Skak Madsen; Olivia Svolgaard; Morten Blinkenberg; Hartwig Roman Siebner; Kasper Winther Andersen
Journal:  Neuroimage Clin       Date:  2020-08-25       Impact factor: 4.881

2.  Cerebellar and premotor activity during a non-fatiguing grip task reflects motor fatigue in relapsing-remitting multiple sclerosis.

Authors:  Olivia Svolgaard; Kasper Winther Andersen; Christian Bauer; Kristoffer Hougaard Madsen; Morten Blinkenberg; Finn Selleberg; Hartwig Roman Siebner
Journal:  PLoS One       Date:  2018-10-24       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.